Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for his achievements in the life sciences, healthcare, diagnostics, healthcare IT industries and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications with others pending. He currently serves as a General Partner at New Ventures Funds. Before joining New Ventures Funds, he served as an Entrepreneur-In-Residence to GE Ventures – New Business Creation Group, leading to the founding of Evidation Health and DrawBridge Health. He currently serves on the public boards of GeneNews Ltd. (GEN.TO) and Biocartis (BCART.BR) and Transparency Life Sciences (Private). He is also a co-founder and an advisory board member to DrawBridge Health. Previously, he co-founded and held the position of Managing Director and head of consulting services for Scientia Advisors, a company that became the go-to provider of strategic advice and implementation services for next-generation healthcare and life science innovators and Global 25 market leaders before its acquisition by Precision for Medicine in November of 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories. Mr. Glorikian holds an MBA from Boston University and a bachelor's degree in Biology from San Francisco State University. Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News, and has been quoted regularly by Dow Jones, The Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many other media outlets. He is the author of two books: Commercializing Novel IVD’s; A Comprehensive Manual for Success and MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market and the host of the MoneyBall Medicine™ podcast series.